G

GSK

Develops medicines, vaccines, and consumer health

Principal Forward Deployed Engineer

Full-TimeUpdated on 10/20/2026
No salary listed
Expert
Master's, PhD
London, UK
Hybrid
Engineering ManagementEngineering Leadership

About the job

Requirements
  • A PhD or master’s degree in Computer Science or Software Engineering, or equivalent practical experience.
  • At least 12 years of experience in software engineering and AI/ML engineering, including significant time leading senior engineering teams or functions.
  • Demonstrated experience taking AI ideas from sketch to working software quickly in customer-facing engineering roles.
  • Strong technical depth in generative AI patterns, including agents, multi-agent orchestration, retrieval-augmented generation, and evaluation.
  • Daily use of AI coding agents, such as Claude Code, GitHub Copilot, or Databricks AI Assistant, as the primary mode of development.
  • Experience hiring, mentoring, and developing senior engineering talent.
  • A track record of representing engineering functions to senior business stakeholders.
  • Hands-on experience with Openclaw or Hermes agents.
Responsibilities
  • Lead the Forward Deployed Engineering function, including its strategy, structure, hiring, development, and standards.
  • Hire, mentor, and develop the FDE team, creating development paths from G8 through G5.
  • Set standards for AI-native engineering practice within the function, including agent workflows, prompt and pattern libraries, and handoff hygiene.
  • Own relationships with Director- and Senior Director-level business-unit sponsors across business units that bring AI use cases to Enterprise AI.
  • Personally take on the most strategic FDE engagements that set precedents for the function.
  • Make and defend portfolio-level kill-or-continue decisions across FDE engagements with business-unit and Enterprise AI leadership.
  • Coordinate with Solutions Engineering and Operations Engineering on the delivery pipeline, and represent FDE in Enterprise AI leadership forums.
  • Influence vendor strategy and tooling choices for AI-native engineering practice within Enterprise AI.
  • Ensure the FDE function operates within Code Orange, Responsible AI, and Accountability Report governance from the prototype stage onward.
  • Provide regular reporting to Enterprise AI leadership on FDE function performance, including engagement pipeline, outcomes, team development, and capacity.
Desired Qualifications
  • Prior leadership experience at an AI-native company such as Anthropic, Palantir, OpenAI, or a similar organization, as Head of Forward Deployed Engineering, Director of Solutions, or equivalent.
  • Experience in regulated industries such as pharmaceuticals, healthcare, or financial services.
  • Experience setting AI engineering standards at organizational scale.
  • Clinical development experience.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Yahoo Finance
Oct 25th, 2026
HUTCHMED licenses HMPL-A830 to GSK in a deal worth up to $1.3B, with $110M upfront

HUTCHMED (China) has closed an exclusive licence agreement giving a GSK subsidiary rights to develop and commercialise HMPL-A830 worldwide, outside Mainland China, Hong Kong, Macau, and Taiwan. HUTCHMED receives $110 million upfront, plus up to $1.185 billion in potential milestones and tiered royalties. The GSK subsidiary will bear later-stage development and commercialisation costs. HUTCHMED keeps global Phase I responsibility and Greater China rights. The deal partly diversifies a business that still relies on a few oncology drugs, such as fruquintinib and savolitinib, and on China sales.

Yahoo Finance
Oct 24th, 2026
GSK's $2.2B Zantac charge tests whether specialty medicines can carry Q3 results

GSK reports third-quarter results on October 28, with a $2.2 billion Zantac settlement charge weighing on the numbers. Consensus expects earnings per share to fall 9% year on year to $1.33, while revenue is forecast at $8.81 billion against $8.55 billion a year ago. The settlement resolves 93% of outstanding US state court cases. Investors will watch how management separates the charge from core results. Specialty Medicines grew 14% last quarter. Long-acting HIV injectables Cabenuva and Apretude rose 33% and 39%, driving 80% of ViiV's growth. The key launch to track is Exdensur, whose J-code went live on July 1. More than 50% of insured patients now have coverage, so new patient starts will be the key metric.

Pharmaceutical Executive
Oct 23rd, 2026
CSL names Deborah Waterhouse as CEO and manager director.

CSL names Deborah Waterhouse as CEO and manager director. Deborah Waterhouse is leaving ViiV Healthcare to become CEO and managing director of CSL. ViiV Healthcare has announced that Deborah Waterhouse is stepping down as chief executive officer of ViiV Healthcare and president of GSK Global Health to join CSL as chief executive officer and managing director. Lynn Baxter, currently president of GSK Europe, is set to be appointed chief executive officer of ViiV Healthcare and president of GSK Global Health, effective November 1, 2026.[1] Waterhouse's move to CSL is set to take effect February 1, 2027, following an extensive global search conducted by CSL's board. What does this mean for ViiV and CSL? Waterhouse has led ViiV Healthcare since 2017, with the company reporting sales of $10.2 billion during GSK's 2025 financial year.[1] She also served as president of GSK Global Health, a role she will relinquish alongside the ViiV CEO post. Baxter was previously leading ViiV's U.S. business for six years before moving into her current GSK Europe role, and will now oversee both ViiV Healthcare and GSK Global Health.[1] Waterhouse is expected to work with Baxter on a transition at ViiV before departing. At CSL, Gordon Naylor will continue serving as interim CEO and managing director until Waterhouse's February 2027 start date, after which he will return to the CSL board as a non-executive director.[1,2] Waterhouse will retain her base in the U.K. while spending significant time in Australia, the U.S., and CSL's other major markets and operational centers.[1,2] What is Waterhouse's track record? Waterhouse brings more than 25 years of experience managing complex global specialty pharma businesses across the U.S., U.K., continental Europe, and Australia. Before ViiV, she was the leader of GSK's U.S. vaccines business and its U.S. primary care business, along with serving as GSK's general manager for Australia and New Zealand between 2008 and 2012.[1] CSL frames her ViiV tenure as evidence she can deliver the combination of commercial growth and pipeline renewal the company says it is seeking in its next chapter. GSK leadership credits Waterhouse's tenure with both commercial and mission-driven results. "During her tenure as CEO, ViiV advanced important innovations in HIV treatment and prevention, expanded patient access to medicines, delivered sustained business growth, and strengthened its long-term strategic position," says David Redfern, chairman of the ViiV board and president of corporate development at GSK. On Baxter's appointment, he adds that her "deep experience across the biopharmaceutical industry, proven commercial leadership, and longstanding commitment to patients position her well to lead ViiV Healthcare through its next phase of growth." CSL chair Brian McNamee points to specific capabilities behind the board's decision. "She has grown a focused biopharmaceutical business and renewed the franchise at ViiV by driving the development and commercialization of the next generation of medicines to support patients," he says. "She knows the United States, she knows Australia and she knows how to build pipelines and manage partnerships." McNamee said the board's decision to appoint Waterhouse was unanimous.[2] Waterhouse addressed both moves directly. On her ViiV exit: "It has been a privilege to lead ViiV Healthcare and GSK Global Health and work alongside so many talented colleagues, partners, and advocates." She then touched on joining CSL, saying, "The foundations are strong. My job is to continue the momentum and evolve the path into reliable growth for patients and shareholders. ViiV Healthcare has reshaped the treatment and prevention landscape for people impacted by HIV. I am honored to take on this role and look forward to working with colleagues around the world to continue advancing innovation."

Yahoo Finance
Oct 23rd, 2026
GSK shares up 20.4% despite 5.2% net margin as $10.6B Nuvalent deal lifts pipeline hopes

GSK shares have risen 20.4% over the past year, including dividends, even as the company's profitability weakened. The stock now trades at £19.14, up from £16.52 at the start of the period. Revenue reached £8,409m, but net income slipped to £435m and net margin fell to 5.2%. GSK agreed to buy Nuvalent for $10.6 billion to deepen its lung cancer pipeline. It also won approvals for Jideytro, Hibsago, and the new antibiotic Utebzi. The bullish case puts fair value at £23.63, assuming 8.5% annual revenue growth and margins rising to 19.8% by 2028. The bearish case puts it at £11.2, citing cost pressure, HIV patent expiries, and pricing and legal risks. GSK plans to fund growth through a £1.9 billion cost-saving programme and site closures.

UAE News
Oct 21st, 2026
Mubadala Bio's IDS, GSK sign strategic partnership to expand access to GSK's general medicines across UAE.

Mubadala Bio's IDS, GSK sign strategic partnership to expand access to GSK's general medicines across UAE. WAM 21 Oct 2026, 18:26 GMT+ ABU DHABI, 21st October, 2026 (WAM) - Mubadala Bio's IDS and GSK today announced a strategic alliance partnership to support the UAE's healthcare priorities and ambitions to strengthen healthcare resilience and develop a world-class life sciences ecosystem. The agreement was signed by Khalid Alkaf, General Manager - Pharma Logistics, Mubadala Bio, and Boyd Chongphaisal, Vice President & General Manager, GSK Gulf, and witnessed by Hamad Almarzooqi, Group Deputy Chief Executive Officer, Mubadala Bio, and Mohamed El Dababy, President, International Central Region, GSK, at the Abu Dhabi Future Health Summit. Under the partnership, IDS will manage the sales, marketing, distribution and promotion of GSK's General Medicines portfolio in the UAE, comprising more than 20 medicines. The collaboration combines IDS's deep local market expertise and capabilities with GSK's global scientific leadership and healthcare portfolio, supporting the development of local pharmaceutical capabilities and creating long term value for patients and healthcare providers in the UAE. The partnership brings together complementary strengths and expertise, demonstrating the value of collaboration between global healthcare leaders and national champions in supporting better health outcomes for the UAE and beyond.